Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.58 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.58 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.58 |
| ▸ | HINT1 | P49773 | 3/20 | 0.52 |
| ▸ | TYMP | P19971 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 2/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16359949 | 1.00 | POLB (0.70) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL442294 | 0.91 | POLB (0.71) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL8490891 | 0.91 | POLB (0.71) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL3744960 | 0.90 | POLB (0.68) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL15012843 | 0.90 | POLB (0.70) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL15798769 | 0.90 | POLB (0.70) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL3751858 | 0.89 | POLB (0.67) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL8622463 | 0.89 | POLB (0.67) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL8622459 | 0.89 | POLB (0.67) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL27984215 | 0.89 | POLB (0.64) | POLBP2RY2P2RY4P2RY6HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 559 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | claimed |
| EP-2010659-A2 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | Epicentre Technologies (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120863-A2 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | EPICENTRE TECHNOLOGIES (US) | 2007-10-25 | — | — | WO | claimed |
| EP-0767842-B1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | UNIV WASHINGTON (US) | 2000-09-27 | — | — | EP | claimed |
| EP-1004675-A2 | Methods of screening for nucleoside analogs that are incorporated by HIV reverse transcriptase and cause incorrect base pairing | DARWIN MOLECULAR CORPORATION (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0767842-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996000797-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORP (US) | 1996-01-11 | — | — | WO | claimed |
| JP-5273209-A | — | — | None | — | — | JP | disclosed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-12559748-B2 | Compositions and methods for the treatment of hemoglobinopathies | NOVARTIS AG (CH) | 2026-02-24 | — | — | US | disclosed |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | APTAH BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| EP-0700442-A1 | IMMORTALIZED HUMAN CELL LINES CONTAINING EXOGENOUS CYTOCHROME P450 GENES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-13 | — | — | EP | disclosed |
| WO-1996000797-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORP (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0625985-A1 | METHOD AND RING-OPENED PURINE COMPOUNDS FOR LABELING POLYNUCLEOTIDES. | UNIV MIAMI (US) | 1994-11-30 | — | — | EP | disclosed |
| WO-1994026905-A1 | IMMORTALIZED HUMAN CELL LINES CONTAINING EXOGENOUS CYTOCHROME P450 GENES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-11-24 | — | — | WO | disclosed |
| JP-H05273209-A | DNA DETECTING KIT | TAKARA SHUZO CO LTD | 1993-10-22 | — | — | JP | disclosed |
| WO-1993011146-A1 | METHOD AND RING-OPENED PURINE COMPOUNDS FOR LABELING POLYNUCLEOTIDES | UNIVERSITY OF MIAMI (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | POLB 4/4885P2RY2 181/4885P2RY4 141/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | POLB 82/4885P2RY2 4635/4885P2RY4 4783/4885 |
| US-12559748-B2 | Compositions and methods for the treatment of hemoglobinopathies | HBZ, HBB, HBG1 | POLB 796/4885P2RY2 4325/4885P2RY4 4394/4885 |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRNP, UPF1, FUS | POLB 387/4885P2RY2 1969/4885P2RY4 1893/4885 |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | POLB 1956/4885P2RY2 618/4885P2RY4 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.